SQZ BIOTECHNOLOGIES CO (SQZ) Stock Overview
USA - NYSE:SQZ - US78472W1045 - Common Stock
SQZ Key Statistics, Chart & Performance
The current stock price of SQZ is 0.435 USD. In the past month the price decreased by -27.5%. In the past year, price decreased by -87.5%.
SQZ Latest News, Press Relases and Analysis
SQZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.85 | 408.76B | ||
| AMGN | AMGEN INC | 13.81 | 162.12B | ||
| GILD | GILEAD SCIENCES INC | 16.03 | 153.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.16 | 109.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.69 | 61.40B | ||
| ARGX | ARGENX SE - ADR | 90.64 | 51.39B | ||
| INSM | INSMED INC | N/A | 34.94B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.1 | 34.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.70B | ||
| NTRA | NATERA INC | N/A | 25.65B | ||
| BIIB | BIOGEN INC | 9.13 | 21.44B |
Related stock screener links
About SQZ
Company Profile
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-10-30. The firm is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Company Info
SQZ BIOTECHNOLOGIES CO
200 Arsenal Yards Blvd, Suite 210
Watertown MASSACHUSETTS 02472 US
CEO: Armon Sharei
Employees: 53
Phone: 16177588672.0
SQZ BIOTECHNOLOGIES CO / SQZ FAQ
What is the stock price of SQZ BIOTECHNOLOGIES CO today?
The current stock price of SQZ is 0.435 USD. The price increased by 61.11% in the last trading session.
What is the ticker symbol for SQZ BIOTECHNOLOGIES CO stock?
The exchange symbol of SQZ BIOTECHNOLOGIES CO is SQZ and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is SQZ stock listed?
SQZ stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for SQZ BIOTECHNOLOGIES CO stock?
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435. Check the SQZ BIOTECHNOLOGIES CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SQZ BIOTECHNOLOGIES CO worth?
SQZ BIOTECHNOLOGIES CO (SQZ) has a market capitalization of 12.83M USD. This makes SQZ a Nano Cap stock.
How many employees does SQZ BIOTECHNOLOGIES CO have?
SQZ BIOTECHNOLOGIES CO (SQZ) currently has 53 employees.
What are the support and resistance levels for SQZ BIOTECHNOLOGIES CO (SQZ) stock?
SQZ BIOTECHNOLOGIES CO (SQZ) has a resistance level at 0.52. Check the full technical report for a detailed analysis of SQZ support and resistance levels.
Is SQZ BIOTECHNOLOGIES CO (SQZ) expected to grow?
The Revenue of SQZ BIOTECHNOLOGIES CO (SQZ) is expected to grow by 65.7% in the next year. Check the estimates tab for more information on the SQZ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SQZ BIOTECHNOLOGIES CO (SQZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SQZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SQZ, evaluating the profitability, health, valuation and growth aspects
- SQZ BIOTECHNOLOGIES CO (SQZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SQZ BIOTECHNOLOGIES CO (SQZ) Sales and EPS estimates to see what analysts future expectations are.
- SQZ BIOTECHNOLOGIES CO (SQZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SQZ BIOTECHNOLOGIES CO (SQZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- SQZ BIOTECHNOLOGIES CO (SQZ) Stock Chart to make your own analysis
- SQZ BIOTECHNOLOGIES CO (SQZ) Latest news and press-releases to stay up to date.
Does SQZ BIOTECHNOLOGIES CO (SQZ) stock pay dividends?
SQZ does not pay a dividend.
When does SQZ BIOTECHNOLOGIES CO (SQZ) report earnings?
SQZ BIOTECHNOLOGIES CO (SQZ) will report earnings on 2023-08-02, after the market close.
What is the Price/Earnings (PE) ratio of SQZ BIOTECHNOLOGIES CO (SQZ)?
SQZ BIOTECHNOLOGIES CO (SQZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.45).
SQZ Technical Analysis
SQZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SQZ. While SQZ seems to be doing ok healthwise, there are quite some concerns on its profitability.
SQZ Financial Highlights
Over the last trailing twelve months SQZ reported a non-GAAP Earnings per Share(EPS) of -2.45. The EPS increased by 7.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SQZ Forecast & Estimates
6 analysts have analysed SQZ and the average price target is 19.38 USD. This implies a price increase of 4355.17% is expected in the next year compared to the current price of 0.435.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 65.7% for SQZ